Is Bias in Clinical AI Good or Bad? It’s More Complicated Than That
We do not need models that pretend every patient has equal or equitable access to care. We need models capable of recognizing disparities and responding to them.
We do not need models that pretend every patient has equal or equitable access to care. We need models capable of recognizing disparities and responding to them.
AI genuinely could reduce barriers, by making health information more conversational, more personalized, and easier to act on. But that only happens if the people building these tools decide, from day one, that accessibility isn’t optional.
Capital is flowing into the broader women’s health ecosystem at a pace we have not seen before. The practices that will capture value from that momentum are the ones that get their operational house in order now.
Innovation in women’s health technology is about improving input data, refining performance criteria and ensuring design assumptions align with biological reality and real-world usage. When those fundamentals are in place, products are more accurate, more trustworthy and more likely to be adopted by clinicians and consumers alike.
Resource-sharing across large networks of hospitals allows people to receive a higher quality of care across the country, regardless of where they live or how well-resourced their local health system may be.
Health systems can turn insights into action, ensuring that preventive care actually happens by combining accurate risk prediction with human outreach and careful planning.
It's not just about awareness but also a call to action for patients, families, employers, payers and policymakers to modernize the systems that shape access to care. It must focus on connecting innovation with the infrastructure that governs approval, coverage and affordability.
VBC models deliver significant benefits for CKD management by coordinating medical, behavioral, and social support through multidisciplinary teams. This approach enables providers to personalize care, address barriers to access, and use data-driven strategies to identify and prioritize high-risk patients.
Salivary testing represents more than a new tool; it’s a scalable strategy to shift care upstream, reduce preventable emergencies, and bring equity to a population too often left behind.
Equity has to be built into the deployment strategy from day one, not treated as a future retrofit. That means prioritizing inclusion not only in the data but in the delivery, and recognizing that inclusive deployment is the foundation for inclusive datasets.
Here are some key insights to help unlock the viability of PDTs to address unmet needs throughout the healthcare ecosystem — for patients and providers alike — and how to take meaningful steps to improve the health experience.
Bringing care to people where they are improves community health outcomes — we must operate with more urgency to shore up care resources in rural areas.
Ideas floated by the Trump Administration and Democrats in Congress aim to expand access to fertility treatment as an essential health benefit. But an influx of patients could collide with an already-brittle system of 430,000 annual cycles, 5,000 embryologists, and long-overdue lab upgrades.
In an environment where speed, equity, and scientific rigor are all imperative, modernizing patient recruitment is no longer a future goal. It is a present necessity.
This requires leveraging technology and partnerships in new ways to break down traditional barriers, designing therapies to fit more seamlessly into patients’ lives, and creating more equitable access to life-sustaining treatments.